Boothbay Fund Management LLC Purchases 369,009 Shares of Vaxcyte, Inc. $PCVX

Boothbay Fund Management LLC lifted its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 286.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 497,740 shares of the company’s stock after acquiring an additional 369,009 shares during the quarter. Vaxcyte accounts for about 0.3% of Boothbay Fund Management LLC’s investment portfolio, making the stock its 12th largest holding. Boothbay Fund Management LLC owned 0.38% of Vaxcyte worth $22,966,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Logos Global Management LP grew its stake in shares of Vaxcyte by 4.0% in the fourth quarter. Logos Global Management LP now owns 650,000 shares of the company’s stock worth $29,991,000 after acquiring an additional 25,000 shares during the period. Caligan Partners LP bought a new stake in shares of Vaxcyte in the fourth quarter worth approximately $78,660,000. ADAR1 Capital Management LLC grew its stake in shares of Vaxcyte by 48.1% in the fourth quarter. ADAR1 Capital Management LLC now owns 315,642 shares of the company’s stock worth $14,564,000 after acquiring an additional 102,578 shares during the period. AQR Capital Management LLC bought a new stake in shares of Vaxcyte in the fourth quarter worth approximately $681,000. Finally, Paradigm Biocapital Advisors LP grew its stake in shares of Vaxcyte by 7.5% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,068,020 shares of the company’s stock worth $187,698,000 after acquiring an additional 283,265 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Up 2.8%

Shares of NASDAQ PCVX opened at $50.67 on Thursday. The firm has a 50 day moving average of $53.74 and a 200 day moving average of $52.69. The firm has a market capitalization of $7.32 billion, a price-to-earnings ratio of -7.36 and a beta of 1.24. Vaxcyte, Inc. has a 12-month low of $29.08 and a 12-month high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the prior year, the company posted ($1.04) EPS. Sell-side analysts predict that Vaxcyte, Inc. will post -7.56 EPS for the current year.

Insider Activity at Vaxcyte

In related news, CAO Elvia Cowan sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the completion of the sale, the chief accounting officer directly owned 28,975 shares in the company, valued at approximately $1,738,500. The trade was a 9.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares of the company’s stock, valued at $7,848,622.88. This trade represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,500 shares of company stock valued at $419,288 over the last 90 days. 3.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. BTIG Research lifted their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Finally, Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Vaxcyte presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.